Technology ID
TAB-3750

Thyclotides for the Development of Clinical Diagnostics and Targeted Therapeutics

E-Numbers
E-108-2020-0
Lead Inventor
Appella, Daniel (NIDDK)
Co-Inventors
Zheng, Hongchao (NIDDK)
Clausse, Victor (NIDDK)
Amarasekara, Harsha (NIDDK)
Applications
Therapeutics
Research Materials
Diagnostics
Lead IC
NIDDK
ICs
NIDDK
This technology includes a new class of oligomeric molecules called thyclotides for diagnostic and therapeutic development. Thyclotides is described where chiral tetrahydrofuran (THF) diamine units are linked together with alternating glycines, and nucleobases are attached to this backbone as sidechains. The thyclotide sequence consists of a series of nucleobases similar to that of a nucleic acid sequence. Thyclotides are easily synthesized and purified with excellent solubility in water. Thyclotide sequences bind to complementary DNA and RNA sequences with very strong affinity. Thyclotides can be used to inhibit PCR amplification, which is useful for application where PCR clamping is needed to suppress amplification of native DNA when trying to detect low levels of mutant DNA. Thyclotides are surprisingly cell-permeable, and can be used to suppress microRNA in cells and therefore effect important biological responses.
Commercial Applications
Development of clinical diagnostics or any RNA-targeted or DNA-targeted therapy, or gene editing.

Competitive Advantages
Thyclotides overcome obstacles of peptide nucleic acids by being water soluble, ability to bind very strongly to complementary DNA and RNA, and being cell permeable.
Licensing Contact:
Tong, Betty
tongb@niddk.nih.gov
Phone: 301-451-7836